Silence Therapeutics PLC Capital Markets Day (3663W)
November 14 2017 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 3663W
Silence Therapeutics PLC
14 November 2017
Silence Therapeutics' 2017 Capital Markets Day
14 November 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, will today host a Capital Markets Day for analysts,
investors and media from 2:15pm to 6:00pm GMT at ME London Hotel,
Strand, London WC2R 1HA.
At the meeting, Silence will provide an update on its
proprietary and innovative RNAi technology platform and on selected
pipeline programmes (Iron Overload Disorders and Alcohol Use
Disorder), as well as an overview of the Company's strategy and
operational setup. Speakers from the Company will include:
-- Dr Annalisa Jenkins, Board Chair
-- Ali Mortazavi, Chief Executive Officer
-- Dr Torsten Hoffmann, Chief Operating Officer
-- Dr Dmitry Samarsky, Chief Scientific Officer
-- Dr Ulrich Zügel, Head of Preclinical Drug Discovery
No material new information will be provided during the
presentations.
Following the Company presentations, Silence will host a panel
discussion on genomics, big data and ways to harness outcomes with
genetic medicines such as RNAi. Five key opinion leaders from
relevant fields will form the panel.
All presentation materials will be available on the company
website at www.silence-therapeutics.com shortly after the event has
concluded.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser Tel: +44 (0)20
and Broker) 7418 8900
James Steel/Oliver Jackson
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAKFDFSNXFFF
(END) Dow Jones Newswires
November 14, 2017 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024